Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 28 04:00PM ET
0.9935
Dollar change
-0.0565
Percentage change
-5.38
%
IndexRUT P/E- EPS (ttm)-1.28 Insider Own13.00% Shs Outstand114.92M Perf Week-12.85%
Market Cap116.94M Forward P/E- EPS next Y-0.87 Insider Trans-1.72% Shs Float102.40M Perf Month-6.27%
Income-146.34M PEG- EPS next Q-0.31 Inst Own63.83% Short Float17.15% Perf Quarter-29.54%
Sales140.46M P/S0.83 EPS this Y2.51% Inst Trans-0.05% Short Ratio13.69 Perf Half Y34.55%
Book/sh-1.45 P/B- EPS next Y28.25% ROA-55.19% Short Interest17.56M Perf Year-58.78%
Cash/sh1.27 P/C0.78 EPS next 5Y- ROE- 52W Range0.62 - 2.53 Perf YTD14.86%
Dividend Est.- P/FCF- EPS past 5Y16.79% ROI-3607.86% 52W High-60.73% Beta0.26
Dividend TTM- Quick Ratio2.99 Sales past 5Y52.21% Gross Margin95.85% 52W Low60.92% ATR (14)0.09
Dividend Ex-Date- Current Ratio3.04 EPS Y/Y TTM29.05% Oper. Margin-94.26% RSI (14)36.92 Volatility6.74% 8.32%
Employees325 Debt/Eq- Sales Y/Y TTM-5.16% Profit Margin-104.18% Recom1.57 Target Price5.21
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-7.62% Payout- Rel Volume1.13 Prev Close1.05
Sales Surprise-3.93% EPS Surprise4.16% Sales Q/Q-14.40% EarningsMay 08 BMO Avg Volume1.28M Price0.99
SMA20-9.62% SMA50-18.96% SMA200-11.44% Trades Volume1,445,086 Change-5.38%
Date Action Analyst Rating Change Price Target Change
Jan-19-23Initiated Piper Sandler Overweight $8
Nov-04-22Upgrade RBC Capital Mkts Sector Perform → Outperform $7 → $10
Feb-09-22Upgrade JP Morgan Underweight → Neutral $8
Nov-19-21Resumed Morgan Stanley Equal-Weight $27 → $10
Aug-06-21Downgrade SVB Leerink Outperform → Mkt Perform $6
Aug-06-21Downgrade RBC Capital Mkts Outperform → Sector Perform $17 → $8
Aug-06-21Downgrade JP Morgan Overweight → Neutral
Jul-02-20Initiated Morgan Stanley Overweight $34
Mar-04-20Initiated Barclays Overweight $30
Jan-17-20Downgrade Wedbush Outperform → Neutral
May-23-24 06:45AM
May-09-24 11:10AM
03:02AM
May-08-24 10:36PM
04:45PM
04:05PM Loading…
04:05PM
12:54PM
09:12AM
07:41AM
07:30AM
07:30AM
May-02-24 04:30PM
May-01-24 04:05PM
Apr-24-24 04:01PM
Apr-01-24 04:05PM
04:05PM Loading…
Mar-06-24 04:05PM
Mar-04-24 11:53PM
Mar-01-24 04:05PM
09:21AM
Feb-29-24 10:03PM
06:15PM
08:40AM
07:50AM
07:30AM
Feb-25-24 01:37PM
Feb-22-24 07:00AM
Feb-14-24 10:00AM
Feb-01-24 04:05PM
Jan-08-24 08:30AM
Jan-03-24 07:00AM
04:05PM Loading…
Jan-02-24 04:05PM
Dec-13-23 08:47PM
Dec-10-23 08:15PM
Dec-06-23 04:00AM
Dec-01-23 04:05PM
Nov-08-23 04:05PM
Nov-06-23 07:00AM
Nov-03-23 12:46PM
Nov-02-23 03:30PM
09:33AM
09:20AM
07:47AM
07:30AM
Oct-30-23 08:00AM
Oct-26-23 07:00AM
Oct-02-23 04:05PM
Sep-26-23 07:00AM
Sep-05-23 04:05PM
Sep-01-23 04:05PM
08:00AM
Aug-17-23 08:44AM
Aug-03-23 02:18PM
Aug-02-23 02:00PM
08:45AM
07:37AM
07:30AM
Aug-01-23 04:05PM
Jul-26-23 07:00AM
Jul-25-23 03:00PM
Jul-19-23 08:00AM
Jul-17-23 04:05PM
Jul-05-23 04:05PM
12:00PM
Jun-28-23 08:00AM
Jun-08-23 07:40AM
Jun-01-23 04:05PM
07:00AM
May-23-23 04:05PM
May-09-23 02:59PM
May-05-23 06:07AM
May-04-23 04:09PM
01:00PM
08:55AM
07:51AM
07:45AM
May-03-23 08:46AM
May-01-23 04:10PM
04:05PM
10:01AM
Apr-27-23 10:03AM
Apr-18-23 01:30PM
Apr-17-23 07:05AM
Apr-14-23 12:00PM
Apr-03-23 04:05PM
Mar-14-23 05:36PM
Mar-08-23 07:00AM
Mar-05-23 08:48AM
Mar-01-23 04:05PM
Feb-21-23 08:00AM
Feb-16-23 06:39PM
Feb-15-23 02:00PM
08:45AM
07:30AM
Feb-09-23 10:01AM
07:00AM
Feb-08-23 07:00AM
Feb-07-23 10:00AM
Feb-01-23 04:05PM
Jan-09-23 08:00AM
Jan-04-23 07:00AM
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Paulson Richard A.President and CEOMay 06 '24Sale1.133,5764,0411,153,697May 07 04:56 PM
Rangwala ReshmaEVP & Chief Medical OfficerApr 22 '24Sale1.176,7897,943342,931Apr 23 04:02 PM
Paulson Richard A.President and CEOApr 04 '24Sale1.293,5634,5961,157,273Apr 05 05:20 PM
Paulson Richard A.President and CEOMar 05 '24Sale1.303,5734,6451,160,836Mar 06 04:14 PM
Paulson Richard A.President and CEOMar 01 '24Sale1.2019,37423,2491,164,409Mar 04 07:36 PM
Mason MichaelEVP, CFO & TreasurerMar 01 '24Sale1.206,1627,394398,756Mar 04 07:39 PM
Poulton StuartEVP, Chief Development OfficerMar 01 '24Sale1.206,1557,386329,511Mar 04 07:40 PM
Rangwala ReshmaEVP & Chief Medical OfficerMar 01 '24Sale1.205,9697,163349,720Mar 04 07:41 PM
Cheng Sohanya RoshanEVP & Chief Commercial OfficerMar 01 '24Sale1.205,1096,131393,509Mar 04 07:37 PM
Mano MichaelSVP, General Counsel&SecretaryMar 01 '24Sale1.203,5764,291277,852Mar 04 07:38 PM
Paulson Richard A.President and CEOFeb 29 '24Sale1.1780,47094,1501,183,783Mar 04 07:36 PM
Mason MichaelEVP, CFO & TreasurerFeb 29 '24Sale1.1727,68732,394404,918Mar 04 07:39 PM
Cheng Sohanya RoshanEVP & Chief Commercial OfficerFeb 29 '24Sale1.1721,84025,553398,618Mar 04 07:37 PM
Mano MichaelSVP, General Counsel&SecretaryFeb 29 '24Sale1.1716,97319,858281,428Mar 04 07:38 PM
Poulton StuartEVP, Chief Development OfficerFeb 29 '24Sale1.1716,31119,084335,666Mar 04 07:40 PM
Rangwala ReshmaEVP & Chief Medical OfficerFeb 29 '24Sale1.1715,66718,330355,689Mar 04 07:41 PM
Mason MichaelEVP, CFO & TreasurerFeb 27 '24Sale1.322,5453,369244,400Feb 29 05:35 PM
Poulton StuartEVP, Chief Development OfficerFeb 15 '24Sale1.335,8477,783163,772Feb 20 04:59 PM
Mason MichaelEVP, CFO & TreasurerFeb 06 '24Sale1.594,2056,671246,945Feb 08 04:36 PM
Paulson Richard A.President and CEOFeb 06 '24Sale1.594,0126,365821,453Feb 08 04:34 PM
Paulson Richard A.President and CEOJan 04 '24Sale0.824,1143,373783,465Jan 08 09:00 PM
Paulson Richard A.President and CEODec 04 '23Sale0.793,6222,861787,579Dec 05 05:03 PM
Paulson Richard A.President and CEONov 06 '23Sale0.923,6063,319791,201Nov 07 05:32 PM
Paulson Richard A.President and CEOOct 04 '23Sale1.273,5894,558794,807Oct 05 04:46 PM
BOHLIN GAREN GDirectorSep 12 '23Buy1.2241,14049,98545,140Sep 12 04:07 PM
Paulson Richard A.President and CEOSep 05 '23Sale1.333,6224,817798,396Sep 06 04:06 PM
Cheng Sohanya RoshanEVP & Chief Commercial OfficerSep 01 '23Sale1.337,4159,872204,086Sep 05 04:27 PM
Mason MichaelEVP, CFO & TreasurerSep 01 '23Sale1.336,9139,203237,817Sep 05 04:30 PM
Mano MichaelSVP, General Counsel&SecretarySep 01 '23Sale1.333,8885,176142,234Sep 05 04:29 PM
Paulson Richard A.President and CEOAug 07 '23Sale1.723,7226,402802,018Aug 08 05:02 PM
Poulton StuartEVP, Chief Development OfficerJul 28 '23Sale1.702,8454,836156,286Aug 01 05:37 PM
Paulson Richard A.President and CEOJul 05 '23Sale1.723,5386,085805,740Jul 06 05:36 PM
Cheng Sohanya RoshanEVP & Chief Commercial OfficerJun 08 '23Sale2.351,8394,322211,501Jun 12 04:07 PM
Paulson Richard A.President and CEOJun 05 '23Sale2.243,5367,922809,278Jun 07 04:11 PM
Mason MichaelEVP, CFO & TreasurerJun 02 '23Sale2.226311,401244,730Jun 05 04:10 PM